I’d say rhino your take on it is spot on to my way of thinking.
The original agreement with Cannvalate was to conduct what I would term more proof of concept trials that were designed so that upon success the company could look to immediate sales on the SAS. The company then made the decision to go for global IP protection and pursuit of the FDA registration pathway. As you rightly point out this is a totally different kettle of fish With commensurately massive upside to boot.
The work on ARDS to date would have nothing to do with the original agreement. All of this pre clinical work was never discussed. Camargo would not come cheap and they are consulting on THREE different pathways concurrently.
I don’t understand the questions around R & D spend to be honest. IHL is now a bonafide BIOTECH story. It’s not a cannabis stock as it keeps getting referred to - sure it may sell cannabis oils and inhalers etc that is growing nicely and will underpin the business but pursuing novel drug development for massive markets where there is no existing pharmacological cure via FDA is BIOTECH and its BIG.
I can’t find a biotech that spent less than us on my watchlist and most of them aren’t doing a lot. There are THREE programs runnning here. To put it in perspective We are currently awaiting results on an in vitro study, 2 animal studies and are waiting for ethics approval for a phase 2 trial into OSA where the probability of success is better than most given the positive prior research conducted by Carley into the use of straight dronabinol for OSA.
Btw has anyone noticed that the company is conducting the trial with The Alfred and that they’ve also submitted for ethics approval at The Alfred? Do you think that puts us in pretty good stead?
Ted
IHL Price at posting:
6.8¢ Sentiment: Buy Disclosure: Held
